228 related articles for article (PubMed ID: 10788687)
1. Feasibility study combining low dose rate (192)Ir brachytherapy and external beam radiotherapy aiming at delivering 80-85 Gy to prostatic adenocarcinoma.
Nickers P; Coppers L; Beauduin M; Darimont M; de Leval J; Deneufbourg J
Radiother Oncol; 2000 Apr; 55(1):41-7. PubMed ID: 10788687
[TBL] [Abstract][Full Text] [Related]
2. High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial.
Dinges S; Deger S; Koswig S; Boehmer D; Schnorr D; Wiegel T; Loening SA; Dietel M; Hinkelbein W; Budach V
Radiother Oncol; 1998 Aug; 48(2):197-202. PubMed ID: 9783892
[TBL] [Abstract][Full Text] [Related]
3. Ultrasound-guided high dose rate conformal brachytherapy boost in prostate cancer: treatment description and preliminary results of a phase I/II clinical trial.
Stromberg J; Martinez A; Gonzalez J; Edmundson G; Ohanian N; Vicini F; Hollander J; Gustafson G; Spencer W; Yan Di
Int J Radiat Oncol Biol Phys; 1995 Aug; 33(1):161-71. PubMed ID: 7543891
[TBL] [Abstract][Full Text] [Related]
4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
5. Preliminary toxicity and prostate-specific antigen response of a Phase I/II trial of neoadjuvant hormonal therapy, 103Pd brachytherapy, and three-dimensional conformal external beam irradiation in the treatment of locally advanced prostate cancer.
Stock RG; Stone NN
Brachytherapy; 2002; 1(1):2-10. PubMed ID: 15062181
[TBL] [Abstract][Full Text] [Related]
6. PSA kinetics after external beam radiotherapy alone or combined with an iridium brachytherapy boost to deliver 85 grays to prostatic adenocarcinoma.
Nickers P; Coppens L; Beauduin M; Sabatier J; Albert A; de Leval J; Deneufbourg JM
Strahlenther Onkol; 2001 Feb; 177(2):90-5. PubMed ID: 11233840
[TBL] [Abstract][Full Text] [Related]
7. High-dose-rate iridium-192 afterloading therapy combined with external beam radiotherapy for T1c-T3bN0M0 prostate cancer.
Jo Y; Hiratsuka J; Fujii T; Takenaka A; Fujisawa M
Urology; 2004 Sep; 64(3):556-60. PubMed ID: 15351592
[TBL] [Abstract][Full Text] [Related]
8. Conformal prostate brachytherapy: initial experience of a phase I/II dose-escalating trial.
Martinez A; Gonzalez J; Stromberg J; Edmundson G; Plunkett M; Gustafson G; Brown D; Yan D; Vicini F; Brabbins D
Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1019-27. PubMed ID: 7493828
[TBL] [Abstract][Full Text] [Related]
9. High-dose-rate brachytherapy as monotherapy for localized prostate cancer: a retrospective analysis with special focus on tolerance and chronic toxicity.
Yoshioka Y; Nose T; Yoshida K; Oh RJ; Yamada Y; Tanaka E; Yamazaki H; Inoue T; Inoue T
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):213-20. PubMed ID: 12694841
[TBL] [Abstract][Full Text] [Related]
10. Dose-volume impact in high-dose-rate Iridium-192 brachytherapy as a boost to external beam radiotherapy for localized prostate cancer--a phase II study.
Pinkawa M; Fischedick K; Treusacher P; Asadpour B; Gagel B; Piroth MD; Borchers H; Jakse G; Eble MJ
Radiother Oncol; 2006 Jan; 78(1):41-6. PubMed ID: 16271785
[TBL] [Abstract][Full Text] [Related]
11. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
Stromberg JS; Martinez AA; Horwitz EM; Gustafson GS; Gonzalez JA; Spencer WF; Brabbins DS; Dmuchowski CF; Hollander JB; Vicini FA
Cancer J Sci Am; 1997; 3(6):346-52. PubMed ID: 9403047
[TBL] [Abstract][Full Text] [Related]
12. [Brachytherapy boost irradiation in the treatment of high risk, localised prostate cancer. Initial national experience in Hungary].
Agoston P; Major T; Somogyi A; Szûcs M; Danczig A; Lövey J; Polgár C; Fodor J; Németh G; Kásler M
Magy Onkol; 2004; 48(1):81-8. PubMed ID: 15105901
[TBL] [Abstract][Full Text] [Related]
13. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study.
Martin T; Baltas D; Kurek R; Röddiger S; Kontova M; Anagnostopoulos G; Dannenberg T; Buhleier T; Skazikis G; Tunn U; Zamboglou N
Strahlenther Onkol; 2004 Apr; 180(4):225-32. PubMed ID: 15057433
[TBL] [Abstract][Full Text] [Related]
14. Three-year results of treatment for prostate cancer with low-dose rate temporary iridium-192 brachytherapy.
Momma T; Saito S; Toya K; Yorozu A; Dokiya T; Murai M
Int J Urol; 2006 Mar; 13(3):218-23. PubMed ID: 16643612
[TBL] [Abstract][Full Text] [Related]
15. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
Hiratsuka J; Jo Y; Yoshida K; Nagase N; Fujisawa M; Imajo Y
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):684-90. PubMed ID: 15183471
[TBL] [Abstract][Full Text] [Related]
16. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report.
Mate TP; Gottesman JE; Hatton J; Gribble M; Van Hollebeke L
Int J Radiat Oncol Biol Phys; 1998 Jun; 41(3):525-33. PubMed ID: 9635698
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer.
Galalae RM; Kovács G; Schultze J; Loch T; Rzehak P; Wilhelm R; Bertermann H; Buschbeck B; Kohr P; Kimmig B
Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):81-90. PubMed ID: 11777625
[TBL] [Abstract][Full Text] [Related]
18. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose.
Raben A; Chen H; Grebler A; Geltzeiler J; Geltzeiler M; Keselman I; Litvin S; Sim S; Hanlon A; Yang J
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1631-8. PubMed ID: 15590195
[TBL] [Abstract][Full Text] [Related]
19. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma.
Zelefsky MJ; Leibel SA; Kutcher GJ; Kelson S; Ling CC; Fuks Z
Cancer J Sci Am; 1995; 1(2):142-50. PubMed ID: 9166467
[TBL] [Abstract][Full Text] [Related]
20. Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland.
Borghede G; Hedelin H; Holmäng S; Johansson KA; Sernbo G; Mercke C
Radiother Oncol; 1997 Sep; 44(3):245-50. PubMed ID: 9380823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]